机构：[1]Clinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Department of Urology, Fudan University Shanghai Cancer Center, Center for Cell and Gene Therapy, Fudan University, Shanghai, China.[2]Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, Hebei, China.重点实验室河北省肿瘤放化疗机制与规程研究重点实验室河北大学附属医院[3]College of Pharmaceutical Sciences, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis, Ministry of Education, Hebei University, Baoding, China.[4]Department of Oncology, Shanghai Medical College, Shanghai Genitourinary Cancer Institute, Shanghai, China.[5]Department of Neurosurgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.[6]Hebei Normal University of Science and Technology, Qinhuangdao, China.[7]Clinical Lab, Affiliated Hospital of Hebei University, Baoding, Hebei, China.河北大学附属医院[8]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.首都医科大学附属北京同仁医院首都医科大学附属同仁医院[9]Department of Hepatological Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei, China.河北大学附属医院[10]CT/MRI room, Affiliated Hospital of Hebei University, Baoding, Hebei, China.河北大学附属医院[11]College of Clinical Medicine, Hebei University, Baoding, China.[12]Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.河北大学附属医院[13]Departments of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang Key Laboratory of Translational Biomedical Engineering, Urumqi, China.[14]Department of Pediatric Orthopedics, Spine Center, Xin Hua Hospital Affiliated to, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mass-spectrometry-based proteomic data of tumour patient plasma samples present opportunities for improving cancer detection. Here we generate plasma proteomic profiles from 2,251 pan-cancer patient samples and investigate potential diagnostic biomarkers. Proteomic subtyping with different dominant tumour types links proteomic features and clinical indicators such as tumour stage. The highly immune-activated subtype, consisting of renal and bladder cancers, shows elevated glucose-insulin metabolism and reduced lipid metabolism. Comparison of the plasma proteome before and after surgery indicates that proteome patterns could be used to monitor post-surgery therapeutic effects. We also develop a binary classified model that distinguishes between tumour types and healthy controls, as well as a multicancer model for pan-cancer classification of proteins that could be useful biomarkers, and validate their performance in an independent cohort. In addition, we find that the plasma proteome, along with clinical indicators, whole blood cells and so on, can distinguish the pathological subtypes of specific tumour types. This study portrays a pan-cancer plasma proteomic landscape, providing information on plasma biomarkers that could help in discovering diagnostic opportunities.
基金：
National Key Research and Development Program of China (2022YFA1303200 [C.D.], 2022YFA1303201 [C.D.], and 2023YFC2505900 [J.W.F.]), National Natural Science Foundation of China (32330062 [C.D.], and 31972933 [C.D.]), sponsored by [2022YFA1303200, 2022YFA1303201, 2023YFC2505900]; National Key Research and Development Program of China [82273792, IT2023C07]; National Natural Science Foundation of China [22XD1420100]; Program of Shanghai Academic/Technology Research Leader [ZJ2019-ZD-004]; Major Project of Special Development Funds of Zhangjiang National Independent Innovation Demonstration Zone; Shanghai Municipal Science and Technology Major Project; Fudan Original Research Personalized Support Project [H2022201044]; Cultivation Project of Precision Medicine Joint Fund of Hebei Natural Science Foundation [C20221002]; Government-funded clinical talents Training Project of Hebei Province [32201215]; Young Scientists Fund of the National Natural Science Foundation of China; National Ten Thousand Plan Young Top Talents [82172817]; Natural Science Foundation of China [22Y11905100]; Shanghai 'Science and Technology Innovation Action Plan' medical innovation research project [23DZ2290800]; Human Phenome Data Center of Fudan university
第一作者机构：[1]Clinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Department of Urology, Fudan University Shanghai Cancer Center, Center for Cell and Gene Therapy, Fudan University, Shanghai, China.
共同第一作者：
通讯作者：
通讯机构：[1]Clinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Department of Urology, Fudan University Shanghai Cancer Center, Center for Cell and Gene Therapy, Fudan University, Shanghai, China.[4]Department of Oncology, Shanghai Medical College, Shanghai Genitourinary Cancer Institute, Shanghai, China.[13]Departments of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang Key Laboratory of Translational Biomedical Engineering, Urumqi, China.
推荐引用方式(GB/T 7714)：
Bai Lin,Lyu Jiacheng,Feng Jinwen,et al.Cancer biomarkers discovered using pan-cancer plasma proteomic profiling[J].NATURE BIOMEDICAL ENGINEERING.2025,doi:10.1038/s41551-025-01448-y.
医学